US Physical Therapy (USPH) Q3 2026 Earnings Call Transcript

U.S. Physical Therapy reported Q3 2026 revenue of $223 million, up 13%, with patient visits increasing 8% to 1.68 million and adjusted EPS rising $0.14 year over year to $0.80. Adjusted physical therapy margin improved 60 basis points to 19% despite a 150-basis-point impact from elevated employee health claims; management reaffirmed full-year EBITDA guidance of $102 million to $106 million. Hospital-affiliation revenue exceeded $25 million and represented more than 13% of total revenue, while credit-facility borrowings rose to $247 million to support acquisitions and repurchases. Management warned health costs may remain elevated in Q4, but cited labor and discretionary-cost controls and a potential multiyear reimbursement tailwind from the planned CMS modifier phaseout beginning in 2027.

Analysis

The key debate is whether USPH is becoming a higher-quality, higher-rate platform or simply booking more revenue through partnerships whose retained economics are not yet transparent. Affiliation ramp can lift reported revenue per visit, but the lack of disclosed partnership-level EBITDA leaves room for a revenue/margin disconnect; partner ownership also means stronger subsidiary value does not accrue wholly to USPH shareholders. Watch cash conversion and PT operating income alongside headline growth.

Near term (Q4): a full-quarter affiliation contribution supports reported rates, but elevated self-insurance claims and seasonal softness in injury prevention can mask underlying operating leverage. The claims are unusually large, but self-insurance creates a recurring tail-risk exposure—not just a one-quarter modeling nuisance. Cost reductions may protect margins, though cutting administrative capacity during EMR and billing transitions could impair collections or service if execution slips.

Over 1–3 months, the next proof points are Q4 margin/cash conversion and 2027 guidance: quantify affiliation EBITDA, billing-transition savings, and the reimbursement effect. CMS methodology changes are a potential multi-year upside, not yet a sound base-case earnings input. The debt-funded mix of acquisitions and repurchases raises the cost of any execution miss; the SOFR hedge limits some rate exposure but not leverage or spread risk. A contrarian risk is that investors capitalize affiliation-driven rate gains before the economics and cash realization are demonstrated.

Key Decisions for Investors

• Consider a modest, staged long in USPH on post-call weakness rather than chasing the growth print. Reassess after Q4 results and 2027 guidance; the thesis needs sustained clinic productivity and better cash conversion, not just higher revenue per visit.
• Keep position size below a typical growth-equity allocation until management provides affiliation-level economics or a credible bridge from partnership revenue to operating income and cash. Verify receivables/DSO trends as legacy billing transitions to centralized operations.
• Falsify the long thesis if mature-clinic volume weakens, PT margins fail to improve despite a full-quarter affiliation contribution, or guidance/cash conversion deteriorates as claims costs persist. Treat CMS reimbursement upside as optionality until the company quantifies it.